ArticleMarine biotechnology (New York, N.Y.)2016
Development of an Efficient Genome Editing Method by CRISPR/Cas9 in a Fish Cell Line.
Article in Marine biotechnology (New York, N.Y.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 94 citations in OpenAlex.
- Efficient Gene Editing in Fish Primary Germline Stem Cells.International journal of molecular sciences · 2026Article
- Characterization of cell lines persistently infected with infectious pancreatic necrosis virus.The Journal of general virology · 2026Article
- N1MΨU-modified mRNA vaccines break the mold in fish by enhancing innate immune activation.Molecular therapy. Nucleic acids · 2026Article
- Unexpected regulatory functions of cyprinid Viperin on inflammation and metabolism.BMC genomics · 2024Article
- Fish cell line: depositories, web resources and future applications.Cytotechnology · 2024Review
- Review
- Effect of a loss of the mda5/ifih1 gene on the antiviral resistance in a Chinook salmon Oncorhynchus tshawytscha cell line.PloS one · 2024Article
- Removal of evolutionarily conserved functional MYC domains in a tilapia cell line using a vector-based CRISPR/Cas9 system.Scientific reports · 2023Article
- Article
- CRISPR-Cas- induced IRF3 and MAVS knockouts in a salmonid cell line disrupt PRR signaling and affect viral replication.Frontiers in immunology · 2023Article
- CRISPR/Cas9-Mediated Gene Editing in Salmonids Cells and Efficient Establishment of Edited Clonal Cell Lines.International journal of molecular sciences · 2022Article
- B Chromosomes inAnimals : an open access journal from MDPI · 2022Review
- Role and relevance of fish cell lines in advanced in vitro research.Molecular biology reports · 2022Review
- Sustainable use of CRISPR/Cas in fish aquaculture: the biosafety perspective.Transgenic research · 2022Review
- PIAS Factors from Rainbow Trout Control NF-κB- and STAT-Dependent Gene Expression.International journal of molecular sciences · 2021Article
- A ribonucleoprotein transfection strategy for CRISPR/Cas9-mediated gene editing and single cell cloning in rainbow trout cells.Cell & bioscience · 2021Article
- An efficient vector-based CRISPR/Cas9 system in an Oreochromis mossambicus cell line using endogenous promoters.Scientific reports · 2021Article
- Molecular Characterization ofInternational journal of molecular sciences · 2021Article
- Efficient Genome Editing in Multiple Salmonid Cell Lines Using Ribonucleoprotein Complexes.Marine biotechnology (New York, N.Y.) · 2020Article
- Efficient CRISPR/Cas9 genome editing in a salmonid fish cell line using a lentivirus delivery system.BMC biotechnology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CRISPR/Cas9 system has been used widely in animals and plants to direct mutagenesis. To date, no such method exists for fish somatic cell lines. We describe an efficient procedure for genome editing in the Chinook salmon Oncorhynchus tshawytscha CHSE. This cell line was genetically modified to firstly overexpress a monomeric form of EGFP (cell line CHSE-E Geneticin resistant) and additionally to overexpress nCas9n, a nuclear version of Cas9 (cell line CHSE-EC, Hygromycin and Geneticin resistant). A pre-validated sgRNA was produced in vitro and used to transfect CHSE-EC cells. The EGFP gene was disrupted in 34.6 % of cells, as estimated by FACS and microscopy. The targeted locus was characterised by PCR amplification, cloning and sequencing of PCR products; inactivation of the EGFP gene by deletions in the expected site was validated in 25 % of clones. This method opens perspectives for functional genomic studies compatible with high-throughput screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.